‘Failures aren’t for lack of trying’: The quest to find a drug for Alzheimer’s

file vdb o
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

In February, pharmaceutical companies Roche and Eli Lilly announced that two experimental drugs they had developed for Alzheimer’s disease had failed in clinical trials. Roche’s drug, gantenerumab, and Eli Lilly’s solanezumab joined more than 100 other potential Alzheimer’s drugs that have flopped, including aducanumab, a much-heralded drug from Biogen.

More than 200 promising leads have fallen through just in the past decade. There has been an ongoing search for Alzheimer’s drugs since the 1990s, but “the long and short of it is that it’s not been successful,” says Lon Schneider, an Alzheimer’s researcher at the University of Southern California’s Keck School of Medicine.

These failures aren’t for lack of trying. Instead, they are evidence that the disease and its causes are much more complex than researchers first appreciated. “… Things looked simpler than they really are,” says Richard Hodes, director of the National Institute on Aging (NIA).

Related article:  'Anecdote and feeling over science and fact': Exploring President Trump's embrace of controversial anti-malarial drug

Instead of having a single drug for Alzheimer’s, we might need multiple treatments that target each of the different ways that it can develop and manifest. The drug pipeline has become more diversified, with clinical trials looking at other targets such as inflammation, the immune system and metabolic processes that might be involved in Alzheimer’s, says Heather Snyder, vice president of medical and scientific relations at the Alzheimer’s Association.

Read the original post

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend